mometasone furoate + azelastine hydrochloride

DWJ1656 is a fixed-dose combination intranasal spray developed by Daewoong Pharmaceutical (also known as Great Bear Pharmaceutical) for the treatment of allergic and acute rhinitis. The formulation combines two established active ingredients: **mometasone furoate**, a synthetic corticosteroid, and **azelastine hydrochloride**, a second-generation antihistamine. Mometasone furoate acts as a glucocorticoid receptor agonist to reduce nasal inflammation, while azelastine hydrochloride functions as a selective H1 receptor antagonist and mast cell stabilizer to provide rapid relief from symptoms such as sneezing, itching, and rhinorrhea. This dual-action approach is designed to address both the immediate allergic response and the underlying chronic inflammation associated with rhinitis. The product is marketed in South Korea under the brand name **Moazet** and has undergone Phase 3 clinical trials to establish its efficacy and safety profile.

Brand names

Moazet

Other names

mometasone furoate/azelastine hydrochlorideazelastine/mometasoneazelastine hydrochloride/mometasone furoate